Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: Results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93

Annals of Oncology

Volumn 18, Issue 7, 2007, Pages 1177-1184

  Colleoni, M ^g   Gelber, S ^b   Simoncini, E ^f   Pagani, O ^r   Gelber, R D ^a   Price, K ^b   Castiglione Gertsch, M ^a,p   Coates, A S ^a,ai   Goldhirsch, A ^a,g,r   Thurlimann B ^a,q   Castiglione, M ^a   Collins, J P ^a   Cortes Funes H ^a,o   Green, M ^a,aa   Hiltbrunner, A ^a   Holmberg, S B ^a,k   Hossfeld, D K ^a   Lang I ^a   Lindtner, J ^a,l   Paganetti, F ^a   Rudenstam, C M ^a,k   Stahel, R ^a   Senn, H J ^a,q   Veronesi, A ^a,e   Egli, G ^a,c   Rabaglio, M ^a   Studer, R ^a   Ruepp, B ^a   Maibach, R ^a   Marbot, E ^a   Strausak, M ^a   Gelber, R ^b   Cole, B ^b   Regan, M ^b   Zahrieh, D ^b   Sun, Z ^b   Bernhard, J ^c   Hürny, Ch ^c   Gusterson, B ^a   Viale, G ^a,g   Blacher, L ^d   Celano, J ^d   Isley, M ^d   Hinkle, R ^d   Lippert, S ^d   Scott, K ^d   Crivellari, D ^e   Monfardini, S ^e   Galligioni, E ^e   Magri, M D ^e   Buonadonna, A ^e   Massarut, S ^e   Rossi, C ^e   Candiani, E ^e   Carbone, A ^e   Volpe, R ^e   Roncadin, M ^e   Arcicasa, M ^e   Coran, F ^e   Morassut, S ^e   Marini, G ^f   Marpicati, P ^f   Braga, M ^f   Grigolato, P ^f   Lucini, L ^f   Martinelli, G ^g   Orlando, L ^g   Nole F ^g   Torrisi, R ^g   De Pas, T ^g   de Braud, F ^g   Cinieri, S ^g   Peccatori, F ^g   Luini, A ^g   Orecchia, R ^g   Renne, G ^g   Costa, A ^g   Zurrida, S ^g   Veronesi, P ^g   Sacchini, V ^g   Galimberti, V ^g   Intra, M ^g   Veronesi, U ^g   Ravaioli, A ^h   Tassinari, D ^h   Oliverio, G ^h   Barbanti, F ^h   Rinaldi, P ^h   Pini, E ^h   Drudi, G ^h   Antimi, M ⁱ   Minelli, M ⁱ   Bellini, V ⁱ   Porzio, R ⁱ   Pernazza, E ⁱ   Santeusanio, G ⁱ   Spagnoli, L G ⁱ   Foladore, S ^j   Foghin, L ^j   Pamich, G ^j   Bianchi, C ^j   Marino, B ^j   Murgia, A ^j   Milan, V ^j   Wallgren, A ^k   Ottosson Lonn S ^k   Hultborn, R ^k   Colldahl Jadestrom G ^k   Cahlin, E ^k   Mattsson, J ^k   Ruusvik, O ^k   Niklasson, L G ^k   Dahlin, S ^k   Karlsson, G ^k   Lindberg, B ^k   Sundback A ^k   BergegArdh S ^k   Groot, O ^k   Dahlback L O ^k   Salander, H ^k   Andersson, C ^k   Heideman, M ^k   Nissborg, A ^k   Wallin, A ^k   Claes, G ^k   Ramhult, T ^k   Svensson, J H ^k   Liedberg, P ^k   Nilsson, A ^k   Havel, G ^k   Oestberg, G ^k   Persson, S ^k   Suurkula M ^k   Matusik, J ^k   Erzen, D ^l   Cufer, T ^l   Cervek, J ^l   Cerar, O ^l   Zakotnik, B ^l   Majdic, E ^l   Golouh, R ^l   Lamovec, J ^l   Jancar, J ^l   Vrhovec, I ^l   Kramberger, M ^l   Murray, E ^m   Werner, I D ^m   Dent, D M ^m   Gudgeon, A ^m   Panieri, E ^m   McEvoy, E ^m   Toop, J ^m   Bowen, R ^m   Vorobiof, D ⁿ   Chasen, M ⁿ   Fotheringham, G ⁿ   de Muelenaere, G ⁿ   Skudowitz, B ⁿ   Mohammed, C ⁿ   Rosengarten, A ⁿ   Mendiola, C ^o   Gravalos, C ^o   Colomer, ^o   Mendez, M ^o   Cruz Vigo, F ^o   Miranda, P ^o   Sierra, A ^o   Martinez Tello, F ^o   Garzon, A ^o   Alonso, S ^o   Ferrero, A ^o   Vargas, C ^o   Fey, M F ^p   Dreher, E ^p   Schneider, H ^p   Aebi, S ^p   Buser, K ^p   Ludin, J ^p   Beck, G ^p   Haenel, A ^p   Luthi J M ^p   Altermatt, H J ^p   Nandedkar, M ^p   Oehlschlegel, Ch ^q   Ries, G ^q   Topfer M ^q   Lorenz, U ^q   Ehrsam, A ^q   Spati B ^q   Vogel, E ^q   Cavalli, F ^r   Neuenschwander, H ^r   Bronz, L ^r   Sessa, C ^r   Ghielmini, M ^r   Rusca, T ^r   Rey, P ^r   Bernier, J ^r   Pedrinis, E ^r   Gyr, T ^r   Leidi, L ^r   Pastorelli, G ^r   Herrmann, R ^s   Rochlitz, C F ^s   Harder, J F ^s   Kochli O ^s   Eppenberger, U ^s   Torhorst, J ^s   Piguet, D ^t   Siegenthaler, P ^t   Barrelet, V ^t   Baumann, R P ^t   Pestalozzi, B ^u   Sauter, C ^u   Engeler, V ^u   Haller, U ^u   Metzger, U ^u   Huguenin, P ^u   Caduff, R ^u   Perey, L ^v   Leyvraz, S ^v   Anani, P ^v   Genton, C ^v   Gomez, F ^v   De Grandi, P ^v   Reymond, P ^v   Mirimanoff, R ^v   Gillet, M ^v   Delaloye, J F ^v   Alberto, P ^w   Bonnefoi, H ^w   Schafer P ^w   Krauer, F ^w   Forni, M ^w   Aapro, M ^w   Egeli, R ^w   Megevand, R ^w   Jacot des Combes, E ^w   Schindler, A ^w   Borisch, B ^w   Diebold, S ^w   Egli, F ^x   Forrer, P ^x   Willi, A ^x   Steiner, R ^x   Allemann, J ^x   Ruedi T ^x   Leutenegger, A ^x   Dalla Torre, U ^x   Schonenberger A ^y   Wernli, M ^y   Bargetzi, M ^y   Mingrone, W ^y   Schmid, P ^y   Bartschi E ^y   Beretta, K ^y   Forbes, J F ^a,ad   Lindsay, D ^a   Wilson, A ^a   Preece, D ^a   Simes, R J ^z,ai   Dhillon, H ^z   Collins, J ^aa   Snyder, R ^aa   Abdi, E ^aa   Abraham, R ^aa   Basser, R ^aa   Briggs, P ^aa   Burns, W I ^aa   Chipman, M ^aa   Chirgwin, J ^aa   Ganju, V ^aa   Goss, G ^aa   Haines, I ^aa   Hart, S ^aa   Holmes, R ^aa   Lindeman, G ^aa   McKendrick, J ^aa   McLachlan, S ^aa   McLennan, R ^aa   Mitchell, P ^aa   Richardson, G ^aa   Schwarz, M ^aa   Underhill, C ^aa   Stuart Harris, R ^ab   Malden, T ^ac   Stewart, J ^ad   Ackland, S ^ad   Bonaventura, A ^ad   Jackson, D ^ad   van Hazel, G ^ae,ah   Friedlander, M ^af   Brigham, B ^af   Lewis, C ^af   Bayliss, E ^ag   Chan, A ^ag   Ransom, D ^ag   Trotter, J ^ag   Byrne, M ^ah   Davidson, A ^ah   Dewar, J ^ah   Buck, M ^ah   Beith, J ^ai   Boyer, M ^ai   Sullivan, A ^ai   Tattersall, M H N ^ai   de Souza, P ^aj   Harvey, V J ^ak   Thompson, P ^ak   Porter, D ^ak   more..

^a Harvard School of Public Health and Dana Farber Cancer Institute ^*

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c IBCSG Quality of Life Office   (Switzerland)

^d FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^f SPEDALI CIVILI   (Italy)

^g EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^h Osp Infermi   (Italy)

ⁱ S EUGENIO HOSPITAL   (Italy)

^j General Hospital   (Italy)

^k West Swedish Breast Cancer Study Group   (Sweden)

^l INSTITUTE OF ONCOLOGY   (Slovenia)

^m UNIVERSITY OF CAPE TOWN   (South Africa)

ⁿ Sandton Oncology Center   (South Africa)

^o Madrid Breast Cancer Group   (Spain)

^p UNIVERSITY OF BERN   (Switzerland)

^q CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^r OSPEDALE SAN GIOVANNI   (Switzerland)

^s UNIVERSITY HOSPITAL BASEL   (Switzerland)

^t Hopital Pourtales Neuchatelois   (Switzerland)

^u KANTONSSPITAL   (Switzerland)

^v LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^w Hopital Cantonal   (Switzerland)

^x KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^y CANTONAL HOSPITAL AARAU   (Switzerland)

^z UNIVERSITY OF SYDNEY   (Australia)

^aa CANCER EPIDEMIOLOGY CENTRE   (Australia)

^ab CANBERRA HOSPITAL   (Australia)

^ac FLINDERS MEDICAL CENTRE   (Australia)

^ad NEWCASTLE MATER HOSPITAL   (Australia)

^ae Mount Hospital   (Australia)

^af PRINCE OF WALES HOSPITAL   (Australia)

^ag ROYAL PERTH HOSPITAL   (Australia)

^ah SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^ai ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^aj ST GEORGE HOSPITAL   (Australia)

^ak AUCKLAND CITY HOSPITAL   (New Zealand)

more..

Author keywords

Adjuvant therapy; Chemotherapy; Early stage breast cancer; Estrogen receptor; Hormonal therapy; Lymph node positive

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; TOREMIFENE;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 34547844170     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm091     Document Type: Article

References (26)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: An overview of the randomized trials. Lancet 2005; 365: 1687-1717.
2. Speer JF, Petrosky VE, Retsky MW et al. A stochastic numerical model of breast cancer growth that simulates clinical data. Cancer Res 1984; 44: 4124-4130.
3. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977; 61: 1307-1317.
4. Schnipper LE. Clinical implications of tumor-cell heterogeneity. N Engl J Med 1986; 314: 1423-1431.
5. Shekhar MP, Werdell J, Santner SJ et al. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res 2001; 61 (4): 1320-1326.
6. Wakeling AE, Nicholson RI, Gee JM. Prospects for combining hormonal and nonhormonal growth factor inhibition. Clin Cancer Res 2001; 7 (Suppl 12): S4350-S4355.
7. Lee AV, Cui X, Oesterreich S. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 2001; 7 (Suppl 12): S4429-S4435.
8. Colleoni M, Viale G, Zahrieh D et al. Chemotherapy is more effective in patents with breast cancer not expressing steroid hormone receptors: A study of preoperative treatment. Clin Cancer Res 2004; 10: 6622-6628.
9. Steiner R. Anglostatic activity of anticancer agents in the chick allantoic membrane (CHE-CAM) assay. In Steiner R, Weisz PB, Langer R (eds): Angiogenesis: Key Principles-Science-Technology-Medicine. Basel, Switzerland: Birkhaeuser Verlag 1992; 449-454.
10. International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006; 24 (9): 1332-1341.
11. International Breast Cancer Study Group. Toremifene and tamoxifen are equally effective for early-stage breast cancer: First results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol 2004; 12: 1749-1759.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
13. Greenwood M. The natural duration of cancer. London, England: HM Stationary Office 1926.
14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
15. Cox DR. Regression models and life-tables [with discussion]. J R Stat Soc 1972; 34: 187-220.
16. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I: The value of histological grade in breastEcancer: experience from a large study with long-term follow-up. Histopathology 2002; 41: 151.
17. Norton L, Simon R, Brereton HD et al. Predicting the course of Gompertzian growth. Nature 1976; 264: 542-545.
18. Heuser L, Spratt J, Polk H. Growth rates of primary breast cancer. Cancer (Phil) 1979; 43: 1888-1894.
19. Berry DA, Cirrincione C, Henderson IC et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295 (14): 1658-1667.
20. Anderson WF, Chen BE, Jatoi A, Rosenberg PS. Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat 2006; 100 (1): 121-126.
21. Fisher B, Brown AM, Dimitrov NV. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8 (9): 1483-1496.
22. Goldhirsch A, Coates AS, Colleoni M et al. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: Cyclophosphamide, methotrexate and fluorouracil dose and schedule may make a difference. J Clin Oncol 1998 16: 1358-1362.
23. Colleoni M, Litman HJ, Castiglione-Gertsch M et al. Duration of adjuvant chemotherapy for breast cancer: A joint analysis of two randomized trials investigating three versus six courses of CMF. Br J Cancer 2002; 86: 1705-1714.
24. Colleoni M, Price K, Castiglione-Gertsch M et al. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. Eur J Cancer 1998; 34: 1693-1700.
25. Colleoni M, Li S, Gelber RD et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet 2005; 366: 1108-1110.
26. Colleoni M, Bonetti M, Coates AS et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol 2000; 18 (3): 584-590.